Pharmaceutical Commerce - November/December 2009 - (Page Cover1)

Business Strategies for Pharma/Bio Success www.PharmaceuticalCommerce.com NovemBer/deCemBer 2009 Packaging & drug delivery Brand marketing | Communications Pharma Gets a ‘Just in Time’ Speedup With the Switch to digital Printing ‘Print on demand’ changes traditional design, production and inventory practices for labels, inserts and other printed packaging By F.J. Quinn The full weight of FdA’s regulatory might usually comes down to almost trivially simple elements: the label, insert and related packaging that surround the pharmaceutical product. From black-box warnings, to implementing the new Risk Evaluation and Mitigation Strategies (REMS—see related article), to anticounterfeiting and other brand-protection measures, the physical embodiment of all this attention is slips of paper or film—along with the critically important information printed on them. Thus, a change from the traditional printing technologies, such as offset or flexo printing, to digital printing Fig. 1. Catalent uses the KB KaratPress for short-run digital printing. Credit: KB can shake up many other industry processes. Digital printing, or print on-demand (POD), is simply the same technology used in printers on most office desks, (usually, ink-jet printing), but in industrial printing, the technology is transforming packaging design, invencontinued on page 22 > Industry Tackles the New remS Hurdle FdA’s requirements for risk evaluation and mitigation challenge both new and existing commercialization processes By Suzanne Shelley A key element of the 2007 FDA Amendments Act (FDAA)—the change from “requested” post-marketing compliance plans to mandated Risk Evaluation and Mitigation Strategies (REMS)—has now come to the forefront for both newly approved and commercial biopharmaceuticals. While some REMS are little more than a beefedup patient medication guide, others can involve complicated patient registries and certifications of physicians, pharmacists and even distributors. Moreover, the unexpected announcement of a “classwide” REMS requirement for long-acting opioid drugs last spring (Pharmaceutical Commerce, March p. 24) raises the possibility of programs that potentially will alter the fundamental process of delivering medications to patients. There are the preliminary signs of an industry backlash, as evidenced by the lawsuit filed by Allergan over how a version of its Botox muscle relaxant is marketed (see box). But for the most part, brand managers are marshaling their resources and developing and executing plans per FDA guidance. For service providers to the industry, a minor land rush is on to gain recognition as contractors that can handle the new requirements effectively. “In a healthcare environment where access is already an issue for many patients on multiple other levels, REMS is adding a layer of complexity whose impact will need to be evaluated,” observes Uwe Tigör, MD, SVP of medical strategy for the InVentiv REMS team, InVentiv Health (Saratoga Springs, NY). By design, REMS programs are meant to implement a variety of measures to control prescribing practices, drug handling and utilization in order to safeguard patients and others from adverse events or unintended exposure to the drug. However, industry is increasingly recognizing that these programs have the potential to erect logistical and administrative barriers. These barriers could lead prescribers to select alternative therapies for reasons that have nothing to do with clinical appropriateness and in doing so, restrict a product’s continued on page 14 > Supply Chain | Logistics Cargo Theft emerges as a New Biopharma Worry The signs are apparent that there is organized criminal activity focused on pharma logistics By Nicholas Basta There are two ways to think about in-transit pharmaceutical security to get real serious, real fast: one is to realize that if a single shipment of product gets lost or stolen, the entire lot to which that shipment belonged might be subject to recall—and ask yourself, how much is my product worth on a per-lot basis? The second, more conceptual perspective is to realize that all of the PhD scientists’ work in developing a new pharmaceutical, the expert manufacturing, marketing and sales management, and the high-cost advertising or promotion for that product comes down to a single truck driver, unsupervised, making a delivery to a warehouse or distribution continued on page 19 > What’s Inside Getting value From end-of-Life-Cycle Pharmaceuticals 12 design and Implementation of Physician Segmentation 13 disputing drug Patents 26 http://www.PharmaceuticalCommerce.com

Table of Contents for the Digital Edition of Pharmaceutical Commerce - November/December 2009

Pharmaceutical Commerce - November/December 2009
Contents
Editorial
Op-Ed
Top News
Business & Finance
Brand Marketing | Communications
SupplyChain | Logistics
Information Technology
Packaging & Drug Delivery
Legal | Regulatory
Executive Training & Development
Editorial Index | Meetings

Pharmaceutical Commerce - November/December 2009

https://www.nxtbook.com/nxtbooks/pharmcomm/202003
https://www.nxtbook.com/nxtbooks/pharmcomm/201911
https://www.nxtbook.com/nxtbooks/pharmcomm/201909
https://www.nxtbook.com/nxtbooks/pharmcomm/201906
https://www.nxtbook.com/nxtbooks/pharmcomm/201903
https://www.nxtbook.com/nxtbooks/pharmcomm/201811
https://www.nxtbook.com/nxtbooks/pharmcomm/201809
https://www.nxtbook.com/nxtbooks/pharmcomm/201806
https://www.nxtbook.com/nxtbooks/pharmcomm/20180304
https://www.nxtbook.com/nxtbooks/pharmcomm/20171112
https://www.nxtbook.com/nxtbooks/pharmcomm/20170910
https://www.nxtbook.com/nxtbooks/pharmcomm/20170708
https://www.nxtbook.com/nxtbooks/pharmcomm/20170506
https://www.nxtbook.com/nxtbooks/pharmcomm/20170304
https://www.nxtbook.com/nxtbooks/pharmcomm/20170102
https://www.nxtbook.com/nxtbooks/pharmcomm/20161112
https://www.nxtbook.com/nxtbooks/pharmcomm/20160910
https://www.nxtbook.com/nxtbooks/pharmcomm/20160708
https://www.nxtbook.com/nxtbooks/pharmcomm/20160506
https://www.nxtbook.com/nxtbooks/pharmcomm/20160304
https://www.nxtbook.com/nxtbooks/pharmcomm/20160102
https://www.nxtbook.com/nxtbooks/pharmcomm/20151112
https://www.nxtbook.com/nxtbooks/pharmcomm/20150910
https://www.nxtbook.com/nxtbooks/pharmcomm/20150708
https://www.nxtbook.com/nxtbooks/pharmcomm/20150506
https://www.nxtbook.com/nxtbooks/pharmcomm/20150304
https://www.nxtbook.com/nxtbooks/pharmcomm/20150102
https://www.nxtbook.com/nxtbooks/pharmcomm/20141112
https://www.nxtbook.com/nxtbooks/pharmcomm/coldchaindirectory2014
https://www.nxtbook.com/nxtbooks/pharmcomm/20140910
https://www.nxtbook.com/nxtbooks/pharmcomm/20140708
https://www.nxtbook.com/nxtbooks/pharmcomm/20140506
https://www.nxtbook.com/nxtbooks/pharmcomm/20140304
https://www.nxtbook.com/nxtbooks/pharmcomm/20140102
https://www.nxtbook.com/nxtbooks/pharmcomm/dataservicedirectory
https://www.nxtbook.com/nxtbooks/pharmcomm/20131112
https://www.nxtbook.com/nxtbooks/pharmcomm/20130910_hubreport
https://www.nxtbook.com/nxtbooks/pharmcomm/20130910
https://www.nxtbook.com/nxtbooks/pharmcomm/20130708
https://www.nxtbook.com/nxtbooks/pharmcomm/20130506
https://www.nxtbook.com/nxtbooks/pharmcomm/coldchain2013
https://www.nxtbook.com/nxtbooks/pharmcomm/20130304
https://www.nxtbook.com/nxtbooks/pharmcomm/20130102
https://www.nxtbook.com/nxtbooks/pharmcomm/20121112
https://www.nxtbook.com/nxtbooks/pharmcomm/20120910
https://www.nxtbook.com/nxtbooks/pharmcomm/20120708
https://www.nxtbook.com/nxtbooks/pharmcomm/20120506
https://www.nxtbook.com/nxtbooks/pharmcomm/20120506_coldchain
https://www.nxtbook.com/nxtbooks/pharmcomm/20120304
https://www.nxtbook.com/nxtbooks/pharmcomm/20120102
https://www.nxtbook.com/nxtbooks/pharmcomm/20111112
https://www.nxtbook.com/nxtbooks/pharmcomm/20110910
https://www.nxtbook.com/nxtbooks/pharmcomm/20110708
https://www.nxtbook.com/nxtbooks/pharmcomm/20110506
https://www.nxtbook.com/nxtbooks/pharmcomm/20110304
https://www.nxtbook.com/nxtbooks/pharmcomm/20110102
https://www.nxtbook.com/nxtbooks/pharmcomm/20101112
https://www.nxtbook.com/nxtbooks/pharmcomm/20100910
https://www.nxtbook.com/nxtbooks/pharmcomm/20100708
https://www.nxtbook.com/nxtbooks/pharmcomm/20100506
https://www.nxtbook.com/nxtbooks/pharmcomm/201004
https://www.nxtbook.com/nxtbooks/pharmcomm/201003
https://www.nxtbook.com/nxtbooks/pharmcomm/20100102
https://www.nxtbook.com/nxtbooks/pharmcomm/20091112
https://www.nxtbookmedia.com